earnings
confidence medium
sentiment neutral
materiality 0.50
Bionano reports preliminary Q4/FY 2025 revenue down 2-8% YoY; cash $29.6M
Bionano Genomics, Inc.
2025-FY EPS
reported -$4.85
vs consensus -$1.43
▼ miss
(-239.6%)
- Total Q4 revenue $7.8-8.0M, down 2-4% YoY; full-year $28.4-28.6M, down 7-8%.
- Installed 9 new OGM systems in Q4, 32 in FY; installed base at 387 systems at year-end.
- Cash, equivalents and restricted investments $29.6M as of Dec 31, 2025 ($10.3M restricted).
- Nanochannel array flowcells sold: 7,554 in Q4, 30,171 for full year 2025.
- Preliminary unaudited results; subject to change after year-end close and audit.